US$ 23.03
glp-1 business Receptor Agonist Market Size, Trends and Share Report 2026 GLP-1 Receptor Agonist Market Forecast
Description
ER, extended-release

As of June 2026, compounded semaglutide and tirzepatide prepared by licensed 503A and 503B pharmacies remain available but are in a period of significant regulatory transition

[DOI] [PMC free article] [PubMed] [Google Scholar] 109.Fu Z., Gong L., Liu J., Wu J., Barrett E.J., Aylor K.W., Liu Z

Benefits of GLP-1s Semaglutide is just one of several GLP-1 drugs originally designed to help manage type 2 diabetes by improving blood sugar control